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Hazard and risk assessment of toxic chemicals
is usually focused on individual compounds
and used to limit or regulate exposures. This
approach has been particularly valuable for
setting standards for occupational exposures
and for emissions of various industrial com-
pounds or their byproducts. It is more difﬁ-
cult to develop regulations for chemical
mixtures because compound interactions may
result in additive, synergistic, or antagonistic
effects. The halogenated aromatic (HA)
industrial chemicals and their byproducts are
complex mixtures of polychlorinated
biphenyls (PCBs), polychlorinated dibenzo-p-
dioxins (PCDDs), and polychlorinated
dibenzofurans (PCDFs) that are regulated
using toxic equivalents (TEQs), which inte-
grate the additive contributions of individual
compounds in the mixture (1–5). Risk assess-
ment of HAs initially focused on 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), the
most toxic member of this class of com-
pounds; however, TCDD is a minor compo-
nent of many samples containing PCDDs/
PCDFs. Therefore, hazard and risk assess-
ment of the most highly toxic 2,3,7,8-substi-
tuted PCDDs and PCDFs uses an approach
(Equation 1) where the TEQs of a mixture is
the summation of the concentrations of indi-
vidual congeners times their toxic equivalency
factor (TEF), which is their fractional
potency compared with TCDD (TEF = 1.0).
The biological plausibility of the TEQ
approach is supported by the aryl hydrocar-
bon receptor (AhR)-mediated mechanism of
action for the toxic 2,3,7,8-substituted
PCDDs/PCDFs. TEFs/TEQs have been used
extensively for regulating industrial emissions
of PCDDs/PCDFs and for estimating body
burdens (adipose tissue, blood, and milk) of
these compounds in wildlife and human
populations. However, there are also signiﬁ-
cant problems in applying the TEF/TEQ
approach for estimating toxicity/genotoxicity
and for predicting adverse health effects asso-
ciated with dietary intakes of PCDDs/
PCDFs. The diet contains PCB mixtures,
and their concentrations are orders of magni-
tude higher than the TEQs for PCDDs/
PCDFs. Many individual PCB congeners and
mixtures exhibit AhR antagonist activities,
and the TEQ approach will therefore over-
estimate toxicity (6–9). Moreover, recent
studies have identified a number of phyto-
chemicals, including indole-3-carbinol and
related compounds, bioﬂavonoids, alkaloids,
diverse phenolics, and carotenoids that are
either weak AhR agonists or antagonists
(10–20). The dietary intake and/or serum
levels for some of these compounds are sev-
eral orders of magnitude higher than observed
for HA–TEQs. Potential interactions of phy-
tochemical AhR agonists/antagonists and
HA–TEQs have not been studied extensively;
however, there are examples of inhibition of
TCDD-induced responses by phytochemical
AhR antagonists (10–13,15,16). These inter-
actions have not been incorporated in a
recent U.S. Environmental Protection
Agency (U.S. EPA) evaluation of the poten-
tial adverse effects of current dietary intakes
of HA-derived TEQs. An understanding of
interactions of HAs with high levels of nat-
ural AhR agonists/antagonists in the diet is
required for a science-based risk assessment.
TEQ = Σ PCDDi × TEFi + Σ PCDFi × TEFi      [1]
The development and applications of the
TEF/TEQ approach for TCDD and related
HAs illustrate the utility and limitations of
this method for hazard and risk assessment.
There has been signiﬁcant public, regulatory,
and scientiﬁc concern regarding the potential
adverse health effects of other endocrine-
active chemicals, particularly those com-
pounds that exhibit estrogenic/antiestrogenic,
androgenic/antiandrogenic, and thyroid hor-
monelike activity (21–25). Research in this
area has focused primarily on compounds
that bind hormone receptors, and chemicals
that interact with the ER have been a major
concern. This resulted in a congressional
mandate under the Food Quality Protection
Act and Safe Drinking Water Amendments
(26,27) for the U.S. EPA to develop screen-
ing programs for compounds with estrogenic
and other endocrine activities. These assays
were developed by the Endocrine Disruptor
Screening and Testing Advisory Committee
(EDSTAC) and include a series of both
in vitro and in vivo bioassays that can detect
endocrine-active chemicals (28,29).
Development of Bioassays 
for Estrogenic Compounds
Figure 1 illustrates some industrial com-
pounds that exhibit estrogenic activity. These
include organochlorine pesticides and their
breakdown products/metabolites, phenolics
such as bisphenol A (BPA), hydroxy-PCBs,
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Estrogenic industrial compounds such as bisphenol A (BPA) and nonylphenol typically bind estro-
gen receptor (ER) α and ERβ and induce transactivation of estrogen-responsive genes/reporter
genes, but their potencies are usually ≥ 1000-fold lower than observed for 17β-estradiol. Risk assess-
ment of estrogenic compounds on the basis of their potencies in simple reporter gene or binding
assays may be inappropriate. For example, selective ER modulators (SERMs) represent another class
of synthetic estrogens being developed for treatment of hormone-dependent problems. SERMs dif-
ferentially activate wild-type ERα and variant forms expressing activation function 1 (ER-AF1) and
AF2 (ER-AF2) in human HepG2 hepatoma cells transfected with an estrogen-responsive comple-
ment C3 promoter-luciferase construct, and these in vitro differences reﬂect their unique in vivo
biologies. The HepG2 cell assay has also been used in our laboratories to investigate the estrogenic
activities of the following structurally diverse synthetic and phytoestrogens: 4´-hydroxytamoxifen;
BPA; 2´,4´,6´-trichloro-4-biphenylol; 2´,3´,4´,5´-tetrachloro-4-biphenylol; p-t-octylphenol;
p-nonylphenol; naringenin; kepone; resveratrol; and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane.
The results show that synthetic and phytoestrogens are weakly estrogenic but induce distinct pat-
terns of ER agonist/antagonist activities that are cell context- and promoter-dependent, suggesting
that these compounds will induce tissue-speciﬁc in vivo ER agonist or antagonist activities. These
results suggest that other receptors, such as the aryl hydrocarbon receptor, that also bind structurally
diverse ligands may exhibit unique responses in vivo that are not predicted by standard in vitro
bioassays. Key words: agonists, antagonists, estrogen receptor, estrogens, structure–activity. Environ
Health Perspect 110(suppl 6):925–929 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-6/925-929safe/abstract.html
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nonylphenols, and phthalates. Human expo-
sure to these estrogenic compounds in the diet
is relatively low and is accompanied by signiﬁ-
cantly higher levels of phytoestrogens such as
ﬂavonoids, other hydroxylated aromatics pre-
sent in vegetables, fruits, nuts, and other prod-
ucts (22). The EDSTAC has outlined several
in vitro and in vivo bioassays for estrogenic
compounds (28,29), and these assays can pro-
vide data on relative estrogenic potencies for
individual compounds or estrogen equivalents
(EQs) for mixtures (30,31). For example, we
have used multiple bioassays to show that the
EQs in 200 mL of red wine (30) were at least
1,000 times higher than EQs for the average
daily intake of known estrogenic pesticides in
the diet. The use of individual bioassays and
EQs is comparable to the TEF/TEQ method
for hazard and risk assessment of TCDD and
related HAs and is based on their common
mechanism of action through initial binding
to the ERα or ERβ. The applications and lim-
itations of the TEF/TEQ approach for HAs
have been discussed (7–9), and it is important
to evaluate proposed applications of bioassays
for quantitating synthetic and natural
estrogens (e.g., EQs) and other classes of
endocrine-active compounds.
Structure–Activity
Relationships for
Estrogenic Compounds:
Selective Estrogen
Receptor Modulators
Two ER subtypes (ERα and ERβ) bind
structurally diverse endogenous steroids, phy-
toestrogens, and synthetic chemicals. Relative
binding affinities of estrogenic compounds
for ERα and ERβ are similar for most com-
pounds. 17β-estradiol (E2) and diethylstilbe-
strol bind ERs with high affinity, whereas
most phytoestrogens and synthetic (indus-
trial) compounds bind ERα and ERβ with
relatively low afﬁnity (32–34). In vitro bind-
ing afﬁnities do not distinguish between ER
agonists or antagonists nor do they predict
tissue-specific estrogenic or antiestrogenic
activity. For example, tamoxifen, a widely
used drug for treatment and prevention of
breast cancer, binds ERα and ERβ with mod-
erate affinity and exhibits ER antagonist
(antiestrogenic) activity in breast tumors, but
also exhibits estrogenic activity in the uterus,
bone, and vascular system. Tamoxifen and
selective ER modulators (SERMs) with tis-
sue-specific ER agonist/antagonists are cur-
rently being developed for treatment of
hormone-dependent tumors, vascular disease,
and osteoporosis, and as hormone replace-
ment therapy for postmenopausal women
(35–39). The structure-dependent properties
of SERMs are due, in part, to ligand-induced
conformational changes in the ER that affect
the subsequent tissue-speciﬁc recruitment of
other nuclear factors required for ligand-
induced gene expression and physiologic
responses. X-ray analysis of E2 and SERMs
bound to the ligand-binding domain of ERα
and ERβ confirms that different structural
classes of estrogenic compounds modulate ER
conformation (40–42). We have confirmed
this by showing that interaction profiles of
polypeptides with ligand-bound ERα and
ERβ are highly variable and dependent on
ligand structure (43–48). Further confirma-
tion of ligand structure-dependent activity of
SERMs has been shown in studies with
human HepG cells transfected with an E2-
responsive pC3-luc construct (containing the
human complement C3 promoter linked to a
luciferase reporter gene) and wild-type hERα
or variant forms with a deletion of the activa-
tion factor 1 (AF1) domain (ERα-AF2) or
critical mutations in the AF2 domain (ERα-
AF1) (49,50). Table 1 illustrates the distinct
pattern of induced luciferase activity by E2
and SERMs tamoxifen/4´-hydroxytamoxifen,
ICI 182,780, and raloxifene. These in vitro
differences are consistent with the unique
biologies of these compounds in estrogen-
responsive tissues/organs (50).
Activation of Wild-Type and
Variant hERα by Synthetic
and Natural Estrogenic
Compounds
Most studies on synthetic/industrial estro-
genic compounds and phytoestrogens indi-
cate that these compounds are weakly active
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Figure 1. Structures of synthetic and naturally occurring estrogenic compounds.
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Table 1. Activation of pC3-luc in HepG2 cells
treated with SERMs (55).
SERM hERα hERα-AF1 hERα-AF2a
E2 (10–9 M) +++ +++ 0
Tamoxifen +a +0
Raloxifene 0 +
ICI 164,384 0 0 0
+, significant (p < 0.05) induction (<40% of E2; +++, repre-
sents maximal (100%) induction by E2. ahERα-AF2 does not
activate pC3-luc in HepG2 cells with E2 or SERMs.Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 6 | DECEMBER 2002 927
in ER binding, reporter gene, or cell prolifer-
ation assays (32–34). Both natural and syn-
thetic estrogenic compounds are characterized
by the structural diversity in their back-
ground ring structures and substituents
(51,52). E2 and estrone contain tetracyclic
ring structures with one fully aromatic ring,
and changes in this backbone structure or
aromaticity result in loss of hormonal activ-
ity. In contrast, synthetic/natural estrogenic
compounds include substituted benzenes,
stilbenes, biphenyls, diphenylmethanes,
diphenylethanes, flavones, isoflavones,
flavonols, and polycyclic aromatic com-
pounds. Figure 1 illustrates structurally
diverse synthetic/natural estrogenic com-
pounds used in our studies to investigate the
effects of ligand structure on activation of
estrogen-responsive constructs containing
complement C3 (pC3-luc) or estrogen
response element (ERE) (pERE3) promoter
inserts and cotransfected with hERα, hERα-
AF1, and hERα-AF2 expression plasmids
(53,54). These studies have adapted the
HepG2 cell assay that distinguishes between
the biological activities of SERMs and
include additional cell lines (U2 and MDA-
MB-231 cells) and two promoters (pC3-luc
and pERE3) (53,54). In addition, we investi-
gated partial hERα antagonist activities of
these weakly estrogenic compounds. Results
of initial studies in HepG2 cells using
pC3-luc showed that the phenolic com-
pounds (mono- and dihydroxy) gave similar
but not identical patterns of induced gene
expression clearly different from those
observed for the phytoestrogens naringenin
and resveratrol and the chlorinated hydrocar-
bon kepone (Table 2) (53). Cell context was
also an important determinant for some
responses induced by the phenolics and the
phytoestrogens. For example, resveratrol
induced reporter gene activity in U2 human
osteogenic sarcoma cells transfected with
pC3-luc and hERα-AF1 and naringenin was
inactive, whereas these induction activities
were reversed in U2 cells. In HepG2 cells
cotreated with E2 plus synthetic/natural
estrogens, only BPA (hERα, hERα-AF1, and
hERα-AF2) and naringenin (hERα) exhib-
ited partial antiestrogenic activity with one
or more forms of wild-type or variant hERα,
and these inhibitory effects have also been
observed in vivo in rodent (uterus) studies
(55,56). Ongoing studies using pERE3, wild-
type and variant forms of hERα in HepG2,
U2, and ER-negative MDA-MB-231 breast
cancer cells show that activation of luciferase
activity by natural/synthetic estrogens
depends on ligand structure, cell context and
form of hERα expressed in these ER-nega-
tive cell lines (Table 3) (54). Moreover, using
pERE3, most of the test compounds exhibit
antiestrogenic activity in one or more of
these assays and results of both estrogenic
and antiestrogenic assays also differentiate
between individual phenolic compounds.
The pattern of pC3-luc activation by
BPA and 2,2-bis(p-hydroxyphenyl)-1,1,1-
trichloroethane (HPTE) in HepG2 cells was
similar. However, results obtained using
pERE3 in HepG2, U2, and MDA-MBA-231
cells clearly distinguish between the two 4,4´-
dihydroxydiphenylmethane analogs that dif-
fer only in their methylene bridge
substituents. HPTE and BPA exhibit similar
ER agonist and antagonist activities in
HepG2 cells. However, their activities are sig-
niﬁcantly different in MDA-MB-231 and U2
cells. BPA is consistently a stronger agonist in
MDA-MB-231 and U2 cells transfected with
hERα or hERα-AF1, whereas both com-
pounds exhibit similar activity in U2 cells
transfected with hERα-AF2. Thus, BPA and
HPTE differentially activate variant/wild-
type hERα, and recent studies in our labora-
tories also show that BPA but not HPTE
activates hERβ in HepG2 cells. HPTE acts as
an hERβ antagonist and an androgen recep-
tor antagonist (57,58).
Differences in ligand-dependent activation
of ERα and ERβ are related to ligand-induced
conformational changes in the receptors and
their subsequent recruitment of coactivators
and other nuclear factors required for transac-
tivation. We have used peptide libraries to
identify speciﬁc peptides that exhibit ligand-
dependent interactions with ERα, ERβ, and
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Table 2. Ligand-structure-dependent activation of pC3-luc in HepG2 and U2 cells.
hERα hERα-AF1 hERα-AF2
Natural/synthetic SERM HepG2 U2 HepG2 U2 HepG2 U2
E2 (10–9 M) +++ +++ +++ +++ +++ +++
Phenolics (10–5 M) ++ ++ ++ ++ Variable Variable
Kepone (10–5 M) 0 0 + 0 0 0
Naringenin (10–5 M) 0 0 ++ 0 0 0
Resveratrol (10–5/4 M) 0 0 0 + 0 0
++, significant (p < 0.05) induction (>40% of E2); +, significant (p < 0.05) induction (<40% of E2); +++, represents maximal
(100%) induction by E2. 
Table 3. Comparative ER agonist/antagonist activities of BPA and HPTE in different cell lines transfected
with pERE3 and wild-type or variant forms of hERα (53).
BPA HPTE
Cell line ERα/variant Agonista Antagonistb Agonista Antagonistb
HepG2 hERα +++ + +++ 0
hERα-AF1 + ++ + ++
hERα-AF2 +++ 0 +++ +
MDA-MB-231 hERα ++ 0 + 0
hERα-AF1 + + 0 0
hERα-AF2 ++ 0 0 0
U2 hERα ++ 0 + 0
hERα-AF1 +++ 0 0 0
hERα-AF2 +++ ++ +++ 0
a+, signiﬁcant (p < 0.05) induction (<40% of E2); ++, signiﬁcant (p < 0.05) induction (40–80% of E2); +++, signiﬁcant (p < 0.05)
induction (>80% of E2). b+, signiﬁcant (p < 0.05) inhibition (<40%); +++, signiﬁcant (p < 0.05) inhibition (>40%).
Figure 2. Evaluation of selected xenoestrogens with ERα- and ERβ-selective peptides in HepG2 cells.
Mammalian two-hybrids were performed to characterize the interaction of estradiol (EST), BPA, hydroxy-
tamoxifen (TAM), and HPTE with ERα and ERβ. Each ER expression construct includes the VP16 activation
domain sequence fused 5´ to the complete coding sequence for human ERα (A) and ERβ (B). Human
HepG2 hepatoma cells were transiently transfected with the pVP16-ERα or pVP16-ERβ expression vector
together with a peptide-Gal4DBD fusion construct, a 5XGAL4-TATA-Luc reporter, and the pCMV-β-gal
control plasmid (a constitutively active transfection and toxicity control). Cells were treated with dimethyl
sulfoxide (vehicle control), or the indicated chemical for 24 hr. Luciferase values were normalized to the β-
galactosidase activity. Results are presented as mean values for three separate experiments.
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EST BPA TAM HPTE EST BPA TAM HPTEother nuclear receptors (43–48). Figure 2
summarizes results of mammalian two-hybrid
assays using pVP16ERα or pVP16hERβ and
ER-interacting peptides fused to the DNA
binding domain of the yeast GAL4 protein.
HepG2 cells are transfected with the interact-
ing proteins and the 5XGAL4-Luc reporter
and treated with different concentrations of
E2, tamoxifen, HPTE, or BPA. Previous stud-
ies have demonstrated that interaction of pep-
tide EBIP-49 with hERβ is ligand dependent
(47), and E2 induces reporter gene activity in
HepG2 cells transfected with EBIP-49,
pVP16hERβ, and 5XGAL4-Luc. BPA also
induces activity at the highest concentration
(10–6 M), whereas HPTE and tamoxifen are
inactive (Figure 2). A similar experiment using
pVP16hERα and the class III-F6 peptide (46)
shows that tamoxifen is inactive, whereas E2,
HPTE, and BPA induce reporter gene activity
with different dose–response curves. These
preliminary data from the mammalian two-
hybrid assays complement results showing
that HPTE and BPA differentially activate
pC3-luc (Tables 2, 3) and suggest that syn-
thetic/natural estrogens (e.g., Figure 1) exhibit
SERM-like estrogenic/antiestrogenic activity.
Summary
The TEF/TEQ approach for risk assessment
was developed for chemicals such as HAs that
induce their effects through ligand-activated
receptors. For persistent HA AhR agonists, this
approach has some limited utility. However,
the use of TEFs/TEQs for estimating the toxi-
city of low-level dietary exposures is con-
founded by concurrent exposures to high levels
of phytochemicals that are also AhR
agonists/antagonists. For example, daily TEQ
intakes of TCDD and related compounds are
50–200 pg and serum values < 5 ppt (lipid
weight), or approximately 0.1 pM. In contrast,
total daily intakes of ﬂavonoids can be as high
as 1 g, and serum levels of ﬂavonoids such as
quercitin and genistein can be in the nano-
molar to low micromolar range, where these
compounds act as AhR antagonists (16).
Structure-dependent interactions of SERMs
with hERα and hERβ have been extensively
investigated, and the results suggest that a
TEF/TEQ approach for these compounds is
not appropriate because of their unique tissue-
specific ER agonist/antagonist activities.
Results of this study demonstrate that syn-
thetic/natural estrogenic chemicals also exhibit
SERM-like activity, and in vitro binding or
reporter gene bioassays would not necessarily
predict their estrogenic/antiestrogenic activity
for any given response in vivo. Thus, although
the xenoestrogens resveratrol and naringenin
(Figure 1) exhibit weak binding affinity for
ERα, these data would not predict interactions
with ERβ or other ligand-activated receptors.
In addition there is also evidence that narin-
genin, BPA, and resveratrol exhibit both
ERα agonist and antagonist activities in cell
culture and/or in vivo assays (55,56,59–62).
Resveratrol also interacts with the AhR
(11,15). Ligands that bind other nuclear recep-
tors and the AhR also induce tissue-, species-,
and age-dependent responses, and therefore
development of mechanism-based hazard/risk
assessment of receptor agonists/antagonists
must account for these multiple variables.
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